Industry analysts predict the migraine market will sustain continued growth through 2023

Nov. 25, 2014 - PRLog -- According to the Decisions Resource Group sales of migraine therapies are projected to grow from $3 billion to over $5 billion in the United States, France, Germany, Italy, Spain, United Kingdom and Japan through 2023. The anticipated growth in this sector will be fueled mainly from the launch of two nontriptan acute therapies: Allergan’s orally inhaled dihydroergotamine product Semprana (US launch in 2016), and CoLucid’s 5HT1F receptor agonist lasmiditan (expected launch  beginning in 2018). These two novel therapies will benefit patients seeking nontriptan therapies due to non-response or to cardiovascular risks. Analysts estimate sales of these two medications alone will generate revenue of $1.5 billion by 2023.

The migraine market will also see substantial growth from the launch of five other triptan products according to Pharmacor,  these include: Teva’s Zecuity (sumatriptan transdermal patch), Avanir Pharmaceuticals/OptiNose’s AVP-825 (sumatriptan intranasal powder), Applied Pharma Research/tesa Labtech’s zolmitriptan oral dispersible film (ODF), IntelGenX/RedHill Biopharma’s Rizaport (rizatriptan ODF) and Suda’s SUD-001 (sumatriptan oral spray). $800 million in major-market sales is expected to be generated from these products which will offset the decline in sales from generics.

Allergan’s blockbuster Botox remains a key contributor to the prophylactic market, due to the upsurge of Physicians prescribing Botox to treat chronic migraine.  Botox has few side effects and is considered to be an effective prophylactic treatment option. Pharmacor predicts Botox will contribute to 6 percent annual growth in migraine prophylactic sales through 2023.

CANDIDATES WHO WANT TO BREAK INTO PHARMACEUTICAL SALES!

With such industry leaders paving the way with new therapeutic breakthroughs, they will need both certified and qualified individuals to promote their diversified product portfolio. When industry leaders look for new candidates for sales/marketing positions, they look toward individuals that are industry trained. Companies are looking for people that have the background to sell their product both proficiently and efficiently. The CNPR is a federally trademarked certification you can earn by demonstrating the necessary knowledge in pharmacology, medical terminology, physiology, and regulations for selling pharmaceuticals. The CNPR examination is dedicated to increasing the professional level of NAPSR members and to developing meaningful and ethical standards fully accepted by both its members and members of the pharmaceutical community.

Individuals that are interested in becoming a Certified National Pharmaceutical Representative (CNPR) can contact the National Association of Pharmaceutical Sales Representatives(NAPSRx) for more information or visit the website at http://napsronline.org/